Sign up for free insights newsletter
Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA

DIMEuronext Paris

Need professional-grade analysis? Visit stockanalysis.com

€165.85
+0.88%
End of day
Market Cap

$17.81B

P/E Ratio

67.07

Employees

9,753

Dividend Yield

0.38%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.76-0.86-0.58-0.45-0.82
Calmar-2.14-0.82-0.55-0.19-0.79
Sharpe-1.31-0.56-0.39-0.33-0.57
Omega0.700.920.960.980.91
Martin-3.70-1.94-1.21-0.27-1.55
Ulcer16.2111.8512.6651.6924.57

Sartorius Stedim Biotech SA (DIM) Price Performance

Sartorius Stedim Biotech SA (DIM) trades on Euronext Paris in EUR. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at EUR165.85, up 0.88% from the previous close.

Over the past year, DIM has traded between a low of EUR152.90 and a high of EUR223.00. The stock has lost 9.7% over this period. It is currently 25.6% below its 52-week high.

Sartorius Stedim Biotech SA has a market capitalization of $17.81B, with a price-to-earnings ratio of 67.07 and a dividend yield of 0.38%.

About Sartorius Stedim Biotech SA

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Company Info

Exchange
Euronext Paris
Currency
EUR
Country
France

Financial Metrics

Revenue (TTM)
$2.97B
EBITDA
$778.10M
Profit Margin
8.95%
EPS (TTM)
2.73
Book Value
42.04

Technical Indicators

52 Week High
€224.00
52 Week Low
€148.75
50 Day MA
€196.46
200 Day MA
€192.35
Beta
1.25

Valuation

Trailing P/E
67.07
Forward P/E
35.34
Price/Sales
6.00
Price/Book
4.35
Enterprise Value
$19.98B